PointofLaw.com

FORUM FEATURED DISCUSSIONS PoL COLUMNS LEGAL EXPERTS ARTICLES BOOKS PODCASTS LINKS MASTHEAD ADVANCED SEARCH

FORUM

« NYSE's John Thain | Hyman and Silver: "Medical Malpractice Litigation and Tort Reform: It's the Incentives, Stupid" »

November 12, 2006


Study: Naproxen has anticlotting effect similar to aspirin

Maggie Fox has the story for Reuters. You may recall that plaintiffs' lawyers have been dragging Merck over the coals for daring to suggest that a likely hypothesis for the statistically significant difference between Vioxx and naproxen in its VIGOR study was because of the cardioprotective effect of naproxen.

Posted by Ted Frank at 12:42 AM | TrackBack (0)



categories:
Vioxx/Drug Litigation









 

Published by the Manhattan Institute

The Manhattan Insitute's Center for Legal Policy.